about us
With a scientific foundation built upon collaboration with three renowned institutions – CIBER, Fundación Jiménez Díaz, and CIEMAT – KIJI Tx is delivering a new era of IPSC-MSC engineered cell therapy for the treatment of broad range of inflammatory diseases. These professionalized, engineered MSCs have strong preclinical data and the potential to finally fulfil the long-standing promise of MSCs. Our international team of experienced professionals is committed to bringing these innovative therapies to patients in need.
leadership
Juan A. Bueren, PhD (Chair)
Massimo Dominici, MD PhD
Felipe Prósper, MD PhD
Jean-Frederic Colombel, MD
Mahendra Rao, PhD
Richard Maziarz, MD
Stefanos Theoharis, PhD
Our COLLABORATORS
our investors
science
FIRST PRODUCT KJ01
Why do we need a paradigm for MSC :
- MSC have unfulfilled efficacy
- MSC manufacturing has limitations
We are developing gene engineered iPSC-MSCs with a superior demonstrated efficacy and improved manufacturing, consistency, and flexibility.
Our first products are IPSC-MSCS transduced with IL10 and CXCR4. Strong preclinical data show an improved efficacy through synergistic immunomodulation (IL10) and homing (CXCR4).
In addition, IPSC source offers the consistency needed to guarantee a quality manufacturing of the cells.
PIPELINE / PLATFORM
media
LATEST NEWS
LATEST MATERIAL
LATEST EVENT
JOIN US
CONTACT
